Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age who understand and voluntarily sign an informed consent form.~* Patients treated for pancreatic adenocarcinoma.~Exclusion Criteria:~* Patients currently treated for metastatic pancreatic cancer with other therapy than nab-paclitaxel plus gemcitabine~* Refusal to participate in the study.~* Women who are pregnant or breast-feeding.~* Hypersensitivity to the active substance or to any of the excipients.~* Participation in interventional trials during the period of treatment with nab-paclitaxel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nab-paclitaxel in combination with gemcitabine (AG) (Type: None): The objective is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma. In all cases, the decision to treat the patient with nab-paclitaxel in combination with gemcitabine was already made prior to the decision to enter the subject into the study. Treatment will be according to routine clinical practice and based on recommendations as per Summary of Product Characteristics (SPC).

Based on this trial design, predict the completion outcome and termination type (if applicable).